Truqap is really a kinase inhibitor that works by blocking pathways that assist the cancer cells survive and expand, so lowers cancer progress. Truqap is from a category of medicines called an AKT inhibitor. Truqap received FDA acceptance on November 17, 2023, after good outcomes from your CAPItello-291 Phase III https://rapamycin80134.howeweb.com/35422964/the-5-second-trick-for-sotorasib